Market News & Trends
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
atai Life Sciences N.V. recently launched Invyxis, a new, wholly owned platform company committed to developing new chemical entities (NCEs) and to further pioneering next-generation…
Vivos Therapeutics Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improvement in Reduction of Key Sleep Apnea Metric
Vivos Therapeutics, Inc. recently announced the filing of a US patent application related to certain new and enhanced clinical methods and protocols developed within Vivos’…
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder
Yamo Pharmaceuticals recently announced the first patient has been treated in a Phase 2 study of L1-79 in adolescents and young adults with ASD at…
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
Cocrystal Pharma, Inc. has selected two investigational novel antiviral drug candidates for further development as oral treatments for SARS-CoV-2, the virus that causes COVID-19…..
TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19
TFF Pharmaceuticals, Inc. recently announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial (CT.gov identifier NCT05168644) of a dry…
PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine
PDS Biotechnology Corporation recently announced preclinical data for its universal flu vaccine, which was shown to be effective against….
Provectus Biopharmaceuticals Provides Update on Research into PV-10 Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
Provectus recently provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule) as an immune adjuvant in…
Allergy Therapeutics Announces FDA Clearance of IND Application for Novel Peanut Allergy Vaccine Candidate
Allergy Therapeutics recently announced the US FDA has cleared the Group’s Investigational New Drug application (IND) for its novel virus-like particle (VLP)-based peanut allergy vaccine…
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading Into Phase 2b in Collaboration With Merck
Evaxion Biotech A/S recently announced the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed….
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease With Vascular Pathology
Cyclerion Therapeutics, Inc. recently announced patient dosing has begun in its Phase 2a study in Alzheimer’s Disease with Vascular Pathology (ADv). “The need for effective…
Hepion Pharmaceuticals’ Rencofilstat, in Combination With an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
Hepion Pharmaceuticals, Inc. recently announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor….
Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance
Ajinomoto Bio-Pharma Services, a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Tony O’Neill has joined Aji Bio-Pharma…
Catalent Completes $10-Million Expansion of High Potency Micronization Capabilities at US & UK Facilities
Catalent recently announced it has completed a $10-million expansion in state-of-the-art large-scale isolator units at its Malvern, PA, and Dartford, UK, facilities, to provide advanced…
INmune Bio, Inc. Announces Research Collaboration With Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer
INmune Bio, Inc. recently announced the company has entered into a preclinical research collaboration with Chinese University of Hong Kong (CUHK) to evaluate INKmune -…
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia & Dementia with Lewy Bodies
Athira Pharma, Inc. recently announced patient dosing has begun in SHAPE, a Phase 2 clinical trial of ATH-1017 for the treatment of Parkinson’s disease dementia and Dementia with Lewy bodies….
Sterling Pharma Solutions Expands Early Phase Development Capabilities at Cary, NC, Facility
Sterling Pharma Solutions, a global contract development and manufacturing organization, recently announced it has commenced a $2.1-million expansion project to increase chemical and analytical capabilities…
Monte Rosa Therapeutics & Yeda Announce License & Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
Monte Rosa Therapeutics, Inc. recently announced a license and research collaboration agreement with Dr. Nir London and the Yeda Research and Development Company Ltd., the…
Biomea Fusion Announces First Patient Dosed
Biomea Fusion, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with….
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
Mind Medicine (MindMed) Inc. recently announced the US FDA has cleared MindMed’s Investigational New Drug application, allowing the company’s Phase 2b dose-optimization trial of….
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
Checkpoint Therapeutics, Inc. recently announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody, cosibelimab, administered as…
